Thursday, 22 November 2018

Novartis gets European approval for sight therapy Luxturna

Novartis on Friday said it had received European Union approval for its Luxturna gene therapy to restore sight to people with a rare retinal disease.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)